| Arterial wall response to ex vivo exposure to oscillatory shear stress. | |
| | |
MedLine Citation:
|
PMID: 16179795 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The aim of this study was to analyze the arterial wall response to plaque-prone hemodynamic environments, known to occur mainly in areas of arterial trees such as bifurcations and branching points. In these areas, the vasculature is exposed to cyclically reversing flow that induces an endothelial dysfunction predisposing thus arteries to local development of atherosclerotic plaques. METHODS: We used an ex vivo perfusion system that allows culturing arterial segments under different hemodynamic conditions. Porcine carotid arteries were exposed for 3 days to unidirectional high and low shear stress (6 +/- 3 and 0.3 +/- 0.1 dyn/cm(2)) as well as to oscillatory shear stress (0.3 +/- 3 dyn/cm(2)). This latter condition mimics the hemodynamics present at plaque-prone areas. At the end of the perfusion, the influence of different flow patterns on arterial metabolism was assessed in terms of matrix turnover as well as of smooth muscle cell function, differentiation and migration. RESULTS: Our results show that after 3 days of perfusion none of the applied conditions influence smooth muscle cell phenotype retaining their full contraction capacity. However, an increase in the expression level of matrix metalloproteinase-2 and -9, as well as a decrease in plasminogen activator inhibitor-1 expression were observed in arteries exposed to oscillatory shear stress when compared to arteries exposed to unidirectional shear stress. CONCLUSION: These observations suggest that plaque-prone hemodynamic environment triggers a vascular wall remodelling process and promotes changes in arterial wall metabolism, with important implication in atherogenesis. |
| | |
Authors:
|
Veronica Gambillara; Gabriela Montorzi; Christelle Haziza-Pigeon; Nikos Stergiopulos; Paolo Silacci |
Related Documents
:
|
21132305 - Successful bosentan therapy for pulmonary arterial hypertension associated with heredit... 20496095 - Modelling evolution and the evolving mechanical environment of saccular cerebral aneury... 18515205 - Effect of long-term treatment with risedronate on arterial compliance in osteoporotic p... 21487225 - Comprehensive evaluation of coronary artery disease and aortic atherosclerosis in acute... 16462475 - Repeated endovascular coil occlusion in 350 of 2759 intracranial aneurysms: safety and ... 12239915 - Left gastric venous caval direct shunt in esophagogastric varices. |
Publication Detail:
|
Type: In Vitro; Journal Article; Research Support, Non-U.S. Gov't Date: 2005-09-19 |
Journal Detail:
|
Title: Journal of vascular research Volume: 42 ISSN: 1018-1172 ISO Abbreviation: J. Vasc. Res. Publication Date: 2005 Nov-Dec |
Date Detail:
|
Created Date: 2005-10-17 Completed Date: 2005-12-05 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9206092 Medline TA: J Vasc Res Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 535-44 Citation Subset: IM |
Affiliation:
|
Laboratory of Hemodynamics and Cardiovascular Technology, Swiss Federal Institute of Technology, Lausanne, Switzerland. veronica.gambillara@epfl.ch |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Carotid Arteries / cytology, metabolism, physiology* Cell Proliferation Matrix Metalloproteinase 2 / metabolism Matrix Metalloproteinase 9 / metabolism Muscle, Smooth, Vascular / cytology Myocytes, Smooth Muscle / cytology, physiology Phenotype Plasminogen Activator Inhibitor 1 / metabolism Stress, Mechanical Swine Tissue Distribution Vasoconstriction |
| Chemical | |
Reg. No./Substance:
|
0/Plasminogen Activator Inhibitor 1; EC 3.4.24.24/Matrix Metalloproteinase 2; EC 3.4.24.35/Matrix Metalloproteinase 9 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A vacuolar serine protease (Rho m 2) is a major allergen of Rhodotorula mucilaginosa and belongs to ...
Next Document: The continuing story of endoribonuclease III.